The clinical efficacy of Dermacell AWM is supported by a growing number of peer-reviewed, clinical publications. The clinical efficacy of competing grafts has also been shown in the literature. However, information on cost-effectiveness of those grafts has been lacking. Using the most recent cost data, a meta-analysis determined that higher cost does not necessarily correlate with higher rates of healing. Dermacell AWM is an option that is not only clinically efficacious, but cost-effective too.

Macrophage phenotypes correspond with remodeling outcomes of various acellular dermal matrices

Beyond peer-reviewed publications, there are a number of case studies supporting the use of Dermacell AWM for treating hard-to-heal wounds. From diabetic foot ulcers, to trauma, and burn reconstruction, Dermacell AWM is effective for complete resolution with one application.

Dermacell AWM is a technologically advanced human acellular dermal matrix that is decellularized using Matracell^®, a proprietary, patented, and validated processing technology. Matracell removes a minimum of 97% of donor DNA¹, allowing for rapid cellular infiltration and re-vascularization. Dermacell AWM is terminally sterilized, ready to use without refrigeration or re-hydration.